Cholangiocarcinoma — evolving concepts and therapeutic strategies
Sumera I. Ilyas(Mayo Clinic), Gregory J. Gores(Mayo Clinic in Arizona), Shahid A. Khan(Imperial College London), Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Christopher L. Hallemeier(Mayo Clinic in Arizona)
Cited by 1,715
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.4k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k